Citations

Clear

6273 citation(s) found for "To, Andrew".

Minimum Five-Year Outcomes with Porous Tantalum Acetabular Cup and Augment Construct in Complex Revision Total Hip Arthroplasty
Jenkins, Derek , Odland, Andrew N., Hanssen, Arlen D. , Lewallen, David G. , Jenkins, Derek R, Sierra, Rafael J.

Mayo Clinic

Journal of Bone and Joint Surgery | May 17, 2017 | Volume: 99 | Issue: 10 | Pages: e49

10.2106/jbjs.16.00125 | PMID 28509833 Get It

Background: The use of a trabecular metal revision shell with metal augmentation to fill segmental or irregular defects during complex revision hip arthroplasty has been shown to provide good short-term results in prior published series. Longer-term results of the several cup-augment constructs used clinically are not known. The objective of this study was to report, with minimum 5-year radiographic and clinical follow-up, the outcome of these various constructs in revision total hip arthroplasty. Methods: Eighty-four patients (85 hips) underwent revision total hip arthroplasty with use of porous tantalum augments between 2000 and 2007 at a single institution and were retrospectively reviewed. Fifty-seven of the patients (58 hips) had clinical and radiographic follow-up at a minimum of 5 years. At the time of revision, the majority of the hips had acetabular defects classified as Paprosky Type 3A (28 of 58, 48%) or Type 3B (22 of 58, 38%). Eleven (19%) of the hips also had preoperative pelvic discontinuity. All hips were assessed clinically at a minimum of 5 years with use of the Mayo hip score. Postoperative radiographs were reviewed for implant stability, the presence and location of radiolucent lines and healing of the discontinuity if present. Results: In 2 (3%) of the 58 hips, the constructs failed because of aseptic loosening of the acetabular component and re-revision was indicated. Six (10%) of the 58 hips demonstrated a radiolucent line between the trabecular metal shell and bone in DeLee and Charnley zone 3. In 1 hip that underwent re-revision and in 5 of the 6 hips with a zone-3 radiolucency, a pelvic discontinuity was present at the time of the index revision. The mean preoperative Mayo hip score was 35.7, which improved to 61.9 at 3 months and was 61.7 at the minimum 5-year follow-up. Conclusions: With failure defined as aseptic loosening requiring repeat revision surgery, this cohort demonstrated 97% survivorship and maintained satisfactory hip function at the minimum 5 years after the index revision surgery. Six of the 11 hips with preoperative pelvic discontinuity either failed or developed a radiolucency in zone 3 and are considered at risk for future revision. Pelvic discontinuity should prompt consideration of the addition of adjunctive fixation or the use of alternative techniques. Level of Evidence: Therapeutic Level IV . See Instructions for Authors for a complete description of levels of evidence.
Development of a Unifying Target and Consensus Indicators for Global Surgical Systems Strengthening: Proposed by the Global Alliance for Surgery, Obstetric, Trauma, and Anaesthesia Care (The G4 Alliance)
Haider, Adil H. , Scott, John W. , Gause, Colin D., Meheš, Mira, Hsiung, Grace, Prelvukaj, Albulena, Yanocha, Dana, Baumann, Lauren M., Ahmed, Faheem , Ahmed, Naeem , Anderson, Sara, Angaté, Hervé, Arfaa, Lisa, Asbun, Horacio J. , Ashengo, Tigistu Adamu , Asuman, Kisembo, Ayala, Ruben , Bickler, Stephen W. , Billingsley, Saul, Bird, Peter, Botman, Matthijs , Butler, Marilyn, Buyske, Jo, Capozzi, Angelo, Casey, Kathleen , Clayton, Charles, Cobey, James C., Cotton, Michael , Deckelbaum, Dan, Derbew, Miliard , deVries, Catherine R. , Dillner, Jeanne, Downham, Max, Draisin, Natalie, Echinard, David, Elneil, Sohier , ElSayed, Ahmed , Estelle, Abigail, Finley, G. Allen , Frenkel, Erica, Frykman, Philip K., Gheorghe, Florin, Gore‐Booth, Julian, Henker, Richard , Henry, Jaymie , Henry, Orion, Hoemeke, Laura , Ibanga, Iko, Jackson, Eric V., Jani, Pankaj , Johnson, Walter D. , Jones, Andrew , Kassem, Zeina, Kocan, Abbey, Krishnaswami, Sanjay , Lane, Robert H. , Latif, Asad , Levy, Barbara , Linos, Dimitrios , Linz, Peter E., Listwa, Louis A., Magee, Declan, Makasa, Emmanuel , Marin, Michael L. , Martin, Claude , McQueen, Kelly, Morgan, Jamie , Moser, Richard , Neighbor, Robert, Novick, William M. , Ogendo, Stephen, Omigbodun, Akinyinka , Onajin‐Obembe, Bisola , Parsan, Neil, Philip, Beverly K., Price, Raymond R. , Rasheed, Shahnawaz, Ratel, M, Reynolds, Cheri, Roser, Steven M. , Rowles, Jackie , Samad, Lubna , Sampson, John , Sanghvi, Harshadkumar, Sellers, Marchelle L., Sigalet, David L. , Steffes, Bruce C., Stieber, Erin, Swaroop, Mamta , Tarpley, John L. , Varghese, Asha , Varughese, Julie, Wagner, Richard, Warf, Benjamin C. , Wetzig, Neil , Williamson, Susan , Wood, Joshua, Zeidan, Anne, Zirkle, Lewis G. , Allen, Brendan, Abdullah, Fizan , Asbun, Horacio, Butler, Marilyn, Gheorghe, Florin, Hoffman, David C. , Lane, Robert, Varughese, Julie

Mayo Clinic

World Journal of Surgery | May 15, 2017 | Volume: 41 | Issue: 10 | Pages: 2426-2434

10.1007/s00268-017-4028-1 | PMID 28508237 Get It

AbstractAfter decades on the margins of primary health care, surgical and anaesthesia care is gaining increasing priority within the global development arena. The 2015 publications of the Disease Control Priorities third edition on Essential Surgery and the Lancet Commission on Global Surgery created a compelling evidenced‐based argument for the fundamental role of surgery and anaesthesia within cost‐effective health systems strengthening global strategy. The launch of the Global Alliance for Surgical, Obstetric, Trauma, and Anaesthesia Care in 2015 has further coordinated efforts to build priority for surgical care and anaesthesia. These combined efforts culminated in the approval of a World Health Assembly resolution recognizing the role of surgical care and anaesthesia as part of universal health coverage. Momentum gained from these milestones highlights the need to identify consensus goals, targets and indicators to guide policy implementation and track progress at the national level. Through an open consultative process that incorporated input from stakeholders from around the globe, a global target calling for safe surgical and anaesthesia care for 80% of the world by 2030 was proposed. In order to achieve this target, we also propose 15 consensus indicators that build on existing surgical systems metrics and expand the ability to prioritize surgical systems strengthening around the world.
Intranuclear and higher‐order chromatin organization of the major histone gene cluster in breast cancer
Fritz, Andrew J. , Ghule, Prachi N. , Tye, Coralee E. , Page, Natalie A., Hong, Deli , Shirley, David J. , Weinheimer, Adam, Gerrard, Diana L., Frietze, Seth , Wijnen, André J. van , Zaidi, Sayyed K. , Imbalzano, Anthony N. , Lian, Jane B. , Stein, Janet L. , van Wijnen, Andre J, Boyd, Joseph R. , Barutcu, A. Rasim , Stein, Gary S. , van Wijnen, Andre J

Mayo Clinic

Journal of Cellular Physiology | May 15, 2017 | Volume: 233 | Issue: 2 | Pages: 1278-1290

10.1002/jcp.25996 | PMID 28504305 Get It

Alterations in nuclear morphology are common in cancer progression. However, the degree to which gross morphological abnormalities translate into compromised higher‐order chromatin organization is poorly understood. To explore the functional links between gene expression and chromatin structure in breast cancer, we performed RNA‐seq gene expression analysis on the basal breast cancer progression model based on human MCF10A cells. Positional gene enrichment identified the major histone gene cluster at chromosome 6p22 as one of the most significantly upregulated (and not amplified) clusters of genes from the normal‐like MCF10A to premalignant MCF10AT1 and metastatic MCF10CA1a cells. This cluster is subdivided into three sub‐clusters of histone genes that are organized into hierarchical topologically associating domains (TADs). Interestingly, the sub‐clusters of histone genes are located at TAD boundaries and interact more frequently with each other than the regions in‐between them, suggesting that the histone sub‐clusters form an active chromatin hub. The anchor sites of loops within this hub are occupied by CTCF, a known chromatin organizer. These histone genes are transcribed and processed at a specific sub‐nuclear microenvironment termed the major histone locus body (HLB). While the overall chromatin structure of the major HLB is maintained across breast cancer progression, we detected alterations in its structure that may relate to gene expression. Importantly, breast tumor specimens also exhibit a coordinate pattern of upregulation across the major histone gene cluster. Our results provide a novel insight into the connection between the higher‐order chromatin organization of the major HLB and its regulation during breast cancer progression.
Phase III randomized controlled study of daratumumab, bortezomib, and dexamethasone (DVd) versus bortezomib and dexamethasone (Vd) in patients (pts) with relapsed or refractory multiple myeloma (RRMM): CASTOR study.
Palumbo, Antonio , Chanan‐Khan, Asher , Mateos, María‐Victoria , Qi, Ming , Schecter, Jordan M. , Amin, Himal, Qin, Xiang , Deraedt, William , Ahmadi, Tahamtan , Spencer, Andrew , Sonneveld, Pieter , Weisel, Katja C , Nooka, Ajay K. , Masszi, Tamás , Beksaç, Meral , Špıčka, Ivan , Hungria, Vânia , Mark, Tomer M

Mayo Clinic

Journal of Clinical Oncology | May 11, 2017 | Volume: 34 | Issue: 18_suppl | Pages: LBA4-LBA4

10.1200/jco.2016.34.18_suppl.lba4 Get It

LBA4 Background: Daratumumab (D), a human anti-CD38 IgGκ mAb, induces deep and durable responses with a favorable safety profile in RRMM pts. We report a pre-specified interim analysis of the first randomized controlled study of D (CASTOR; NCT02136134). Methods: Pts with ≥1 prior line of therapy were randomized (1:1) to 8 cycles (q3w) of bortezomib (V)/dexamethasone (d) (V: 1.3 mg/m2sc on Days 1, 4, 8, 11; d: 20 mg po on Days 1, 2, 4, 5, 8, 9, 11, 12) ± D (16 mg/kg iv qw in Cycles 1-3, Day 1 of Cycles 4-8, then q4w until progression). Primary endpoint was PFS. Results: 498 pts (DVd, 251; Vd, 247) were randomized. Baseline demographics and disease characteristics were well balanced. Pts received a median of 2 prior lines of therapy (range 1-10). 66% received prior V; 76% received prior IMiD; 48% received prior PI and IMiD; 33% were IMiD-refractory; 32% were refractory to last line of prior therapy. With median follow-up of 7.4 months, D significantly improved median PFS (61% reduction in risk of progression) and TTP for DVd vs Vd (Table). D significantly increased ORR (83% vs 63%, P <0.0001), and doubled rates of ≥VGPR (59% vs 29%, P <0.0001), and ≥CR (19% vs 9%, P= 0.0012) for DVd vs Vd, respectively; median duration of response was NR vs 7.9 months, respectively. Most common (>25%) AEs (DVd/Vd) were thrombocytopenia (59%/44%), peripheral sensory neuropathy (47%/ 38%), diarrhea (32%/22%) and anemia (26%/31%). Most common grade 3/4 AEs (>10%) were thrombocytopenia (45%/33%), anemia (14%/16%), neutropenia (13%/4%). 7%/9% of pts discontinued due to a TEAE. D-associated infusion-related reactions (45% of pts) mostly occurred during the first infusion; most were grade 1/2 (grade 3/4, 9%/0%). Conclusions: D significantly improved PFS, TTP, and ORR in combination with Vd vs Vd alone. DVd doubled both VGPR and sCR/CR rates vs Vd alone. Safety of DVd is consistent with the known safety profile of D and Vd. The addition of D to Vd should be considered a new standard of care for RRMM pts currently receiving Vd alone. Clinical trial information: NCT02136134. [Table: see text]
Non-V600BRAF Mutations Define a Clinically Distinct Molecular Subtype of Metastatic Colorectal Cancer
Jones, Jeremy , Renfro, Lindsay A. , Al‐Shamsi, Humaid O. , Schrock, Alexa B. , Rankin, Andrew, Zhang, Ben Y., Kasi, Pashtoon Murtaza , Voss, Jesse S. , Leal, Alexis D. , Ali, Siraj M. , Kipp, Benjamin R. , Kopetz, Scott , Wolff, Robert A. , Jones, Jeremy C., Kasi, Pashtoon M, Sun, James, Ross, Jeffrey , Hubbard, Joleen M. , McWilliams, Robert R. , Jones, Jeremy C , Kasi, Pashtoon Murtaza , Sun, James X. , Ross, Jeffrey S , Grothey, Axel , Kopetz, Scott , Al-Shamsi, Humaid O

Mayo Clinic

Journal of Clinical Oncology | May 9, 2017 | Volume: 35 | Issue: 23 | Pages: 2624-2630

10.1200/jco.2016.71.4394 | PMID 28486044 Get It

Purpose Molecular diagnostic testing has become an integral part of the evaluation of patients with metastatic colorectal cancer (CRC). Expanded mutational testing, such as next-generation sequencing (NGS), often identifies mutations with unclear clinical or prognostic implications. One such example is BRAF mutations that occur outside of codon 600 (non-V600 BRAF mutations). Methods We conducted this multicenter, retrospective cohort study to characterize the clinical, pathologic, and survival implications of non-V600 BRAF mutations in metastatic CRC. We pooled patients in whom non-V600 BRAF mutations were identified from NGS databases at three large molecular genetics reference laboratories. Results A total of 9,643 patients with metastatic CRC underwent NGS testing. We identified 208 patients with non-V600 BRAF mutations, which occurred in 2.2% of all patients tested and accounted for 22% of all BRAF mutations identified. Cancers with non-V600 BRAF mutations, compared with cancers with V600E BRAF (V600E BRAF) mutations, were found in patients who were significantly younger (58 v 68 years, respectively), fewer female patients (46% v 65%, respectively), and patients who had fewer high-grade tumors (13% v 64%, respectively) or right-sided primary tumors (36% v 81%, respectively). Median overall survival was significantly longer in patients with non-V600 BRAF-mutant metastatic CRC compared with those with both V600E BRAF-mutant and wild-type BRAF metastatic CRC (60.7 v 11.4 v 43.0 months, respectively; P < .001). In multivariable analysis, non-V600 BRAF mutation was independently associated with improved overall survival (hazard ratio, 0.18; P < .001). Conclusion Non-V600 BRAF mutations occur in approximately 2.2% of patients with metastatic CRC and define a clinically distinct subtype of CRC with an excellent prognosis.
Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma
Kumar, Shaji , Moreau, Philippe , Mateos, María‐Victoria , Shustik, Chaim, Masszi, Tamás , Spencer, Andrew , Hájek, Roman , Romeril, Kenneth, Avivi, Irit , Liberati, Anna Marina , Berg, Deborah, Lin, Jianchang , Gupta, Neeraj , Esseltine, Dixie‐Lee, Richardson, Paul G. , Einsele, Hermann , Gupta, Neeraj , Hari, Parameswaran , Ludwig, Heinz , Minnema, Monique C , Lonial, Sagar , Richardson, Paul Gerard Guy , Hajek, Roman , Moreau, Philippe , Masszi, Tamas

Mayo Clinic

British Journal of Haematology | May 9, 2017 | Volume: 178 | Issue: 4 | Pages: 571-582

10.1111/bjh.14733 | PMID 28485007 Get It

SummaryThe oral proteasome inhibitor ixazomib is approved in the United States, European Union and other countries, in combination with oral lenalidomide and dexamethasone (Rd), for the treatment of patients with multiple myeloma who have received at least one prior therapy. Approval was based on the global, randomised, double‐blind, placebo‐controlled Phase III TOURMALINE‐MM1 study of ixazomib‐Rd (IRd) versus placebo‐Rd in patients with relapsed/refractory multiple myeloma. IRd resulted in a significant improvement in progression‐free survival versus placebo‐Rd (median: 20·6 vs. 14·7 months; hazard ratio 0·74). Common toxicities observed more commonly with IRd versus placebo‐Rd were thrombocytopenia, nausea, vomiting, diarrhoea, constipation, rash, peripheral neuropathy, peripheral oedema and back pain; these were generally grade 1/2 in severity except for thrombocytopenia (19% vs. 9% grade 3/4), which appeared manageable and reversible, with no differences between arms in significant bleeding or dose discontinuations. No cumulative toxicities were observed, indicating the potential feasibility of long‐term IRd treatment. Safety data from TOURMALINE‐MM1 are reviewed and guidance for managing clinically relevant adverse events associated with IRd is provided. Most toxicities were manageable with supportive care and dose delays or reductions as needed. Clinicians should be aware of and understand these potential side effects to optimise and prolong patient benefit.
Finding the grave of Sir William Richard Gowers
Toodayan, Nadeem , Lees, Andrew, Boes, Christopher J.

Mayo Clinic

Practical Neurology | May 4, 2017 | Volume: 17 | Issue: 4 | Pages: 321-322

10.1136/practneurol-2017-001648 | PMID 28473605 Get It

Rendered Speechless
Cowdell, Jed C. , Burton, M. Caroline , Holmes‐Maybank, Keri T. , Harte, Brian , Josephson, S. Andrew , Harris, Dana, Harris, Dana M.

Mayo Clinic

Journal of Hospital Medicine | May 3, 2017 | Volume: 12 | Issue: 5 | Pages: 352-355

10.12788/jhm.2742 | PMID 28459907 Get It

Genetic Landscape of Congenital Myasthenic Syndromes From Turkey: Novel Mutations and Clinical Insights
Yiş, Uluç , Uyanık, Gökhan , Ayanoğlu, Müge , Okur, Derya , Serdaroğlu, Gül, Yılmaz, Sanem , Topaloğlu, Haluk , Anlar, Banu , Çırak, Sebahattin , Engel, Andrew G. , Becker, Kerstin , Kurul, Semra Hız , Bayram, Erhan , Haliloğlu, Göknur , Polat, Ayşe , Tosun, Ayse Fahriye , Yılmaz, Sanem

Mayo Clinic

Journal of Child Neurology | May 3, 2017 | Volume: 32 | Issue: 8 | Pages: 759-765

10.1177/0883073817705252 | PMID 28464723 Get It

Congenital myasthenic syndromes are clinically and genetically heterogeneous disorders of neuromuscular transmission. Most are treatable, but certain subtypes worsen with cholinesterase inhibitors. This underlines the importance of genetic diagnosis. Here, the authors report on cases with genetically proven congenital myasthenic syndromes from Turkey. The authors retrospectively reviewed their experience of all patients with congenital myasthenic syndromes, referred over a 5-year period (2011-2016) to the Child Neurology Department of Dokuz Eylül University, Izmir, Turkey. In addition, PubMed was searched for published cases of genetically proven congenital myasthenic syndromes originating from Turkey. In total, the authors identified 43 (8 new patients, 35 recently published patients) cases. Defects in the acetylcholine receptor (n = 15; 35%) were the most common type, followed by synaptic basal-lamina associated (n = 14; 33%) and presynaptic syndromes (n = 10; 23%). The authors had only 3 cases (7%) who had defects in endplate development. One patient had mutation GFPT1 gene (n = 1; 2%). Knowledge on congenital myasthenic syndromes and related genes in Turkey will lead to prompt diagnosis and treatment of these rare neuromuscular disorders.